FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312185364> ?p ?o ?g. }

• W4312185364 abstract "<sec> <title>BACKGROUND</title> Anthracycline-based chemotherapy has been mainstay of adjuvant breast cancer therapy for decades. Although effective, anthracyclines place long-term breast cancer survivors at risk of late effects, such as reduced cardiorespiratory fitness and increased risk of cardiovascular disease. Previous research has shown beneficial effects of exercise training on cardiorespiratory fitness, but the effects of exercise on limiting factors for cardiorespiratory fitness, cardiovascular risk factors, and patient-reported outcomes in long-term survivors are less clear. Whether previous exposure to breast cancer therapy modulates the effects of exercise is also unknown. </sec> <sec> <title>OBJECTIVE</title> The primary aim of the CAUSE (Cardiovascular Survivors Exercise) trial is to examine the effect of aerobic exercise on cardiorespiratory fitness in anthracycline-treated long-term breast cancer survivors. Secondary aims are to examine effects of exercise training on limiting factors for cardiorespiratory fitness, cardiovascular risk factors, and patient-reported outcomes, and to compare baseline values and effects of exercise training between similar-aged women with and those without prior breast cancer. A third aim is to examine the 24-month postintervention effects of aerobic exercise on primary and secondary outcomes. </sec> <sec> <title>METHODS</title> The CAUSE trial is a 2-armed randomized controlled trial, where 140 long-term breast cancer survivors, 8-12 years post diagnosis, are assigned to a 5-month nonlinear aerobic exercise program with 3 weekly sessions or to standard care. Seventy similar-aged women with no history of cancer will undergo the same exercise program. Cardiorespiratory fitness measured as peak oxygen consumption (VO_2peak), limiting factors for VO_2peak (eg, cardiac function, pulmonary function, hemoglobin mass, blood volume, and skeletal muscle characteristics), cardiovascular risk factors (eg, hypertension, diabetes, dyslipidemia, obesity, physical activity level, and smoking status), and patient-reported outcomes (eg, body image, fatigue, mental health, and health-related quality of life) will be assessed at baseline, post intervention, and 24 months post intervention. </sec> <sec> <title>RESULTS</title> A total of 209 patients were included from October 2020 to August 2022, and postintervention assessments were completed in January 2023. The 24-month follow-up will be completed in February 2025. </sec> <sec> <title>CONCLUSIONS</title> The findings from the CAUSE trial will provide novel scientific understanding of the potential benefits of exercise training in long-term breast cancer survivors. </sec> <sec> <title>CLINICALTRIAL</title> ClinicalTrials.gov NCT04307407; https://clinicaltrials.gov/ct2/show/NCT04307407 </sec> <sec> <title>INTERNATIONAL REGISTERED REPORT</title> DERR1-10.2196/45244 </sec>" @default.
• W4312185364 created "2023-01-04" @default.
• W4312185364 creator A5000866302 @default.
• W4312185364 creator A5012265247 @default.
• W4312185364 creator A5012781036 @default.
• W4312185364 creator A5013706735 @default.
• W4312185364 creator A5015162191 @default.
• W4312185364 creator A5020202420 @default.
• W4312185364 creator A5020934376 @default.
• W4312185364 creator A5056084508 @default.
• W4312185364 creator A5059578423 @default.
• W4312185364 creator A5064557855 @default.
• W4312185364 creator A5067401723 @default.
• W4312185364 creator A5070074773 @default.
• W4312185364 creator A5070680281 @default.
• W4312185364 creator A5081040113 @default.
• W4312185364 creator A5083087105 @default.
• W4312185364 creator A5085214715 @default.
• W4312185364 date "2022-12-22" @default.
• W4312185364 modified "2023-10-06" @default.
• W4312185364 title "Effects of Aerobic Exercise on Cardiorespiratory Fitness, Cardiovascular Risk Factors, and Patient-Reported Outcomes in Long-Term Breast Cancer Survivors: Protocol for a Randomized Controlled Trial (Preprint)" @default.
• W4312185364 cites W1492360552 @default.
• W4312185364 cites W1518659179 @default.
• W4312185364 cites W1535409240 @default.
• W4312185364 cites W1828224642 @default.
• W4312185364 cites W1971487244 @default.
• W4312185364 cites W1989661566 @default.
• W4312185364 cites W1998268494 @default.
• W4312185364 cites W1998733243 @default.
• W4312185364 cites W2000165181 @default.
• W4312185364 cites W2003321779 @default.
• W4312185364 cites W2020693031 @default.
• W4312185364 cites W2042434404 @default.
• W4312185364 cites W2043705607 @default.
• W4312185364 cites W2058397330 @default.
• W4312185364 cites W2081932726 @default.
• W4312185364 cites W2082751083 @default.
• W4312185364 cites W2099449365 @default.
• W4312185364 cites W2101046684 @default.
• W4312185364 cites W2107651401 @default.
• W4312185364 cites W2112802342 @default.
• W4312185364 cites W2113857973 @default.
• W4312185364 cites W2122447448 @default.
• W4312185364 cites W2132322340 @default.
• W4312185364 cites W2134570780 @default.
• W4312185364 cites W2149445224 @default.
• W4312185364 cites W2151501105 @default.
• W4312185364 cites W2153853097 @default.
• W4312185364 cites W2157064067 @default.
• W4312185364 cites W2167096282 @default.
• W4312185364 cites W2167571044 @default.
• W4312185364 cites W2182374763 @default.
• W4312185364 cites W2260466831 @default.
• W4312185364 cites W2561638494 @default.
• W4312185364 cites W2593266874 @default.
• W4312185364 cites W2619353077 @default.
• W4312185364 cites W2735448369 @default.
• W4312185364 cites W2750789564 @default.
• W4312185364 cites W2782723235 @default.
• W4312185364 cites W2793682287 @default.
• W4312185364 cites W2801674502 @default.
• W4312185364 cites W2808328174 @default.
• W4312185364 cites W2886652708 @default.
• W4312185364 cites W2920160432 @default.
• W4312185364 cites W2981067716 @default.
• W4312185364 cites W2981263606 @default.
• W4312185364 cites W3088016615 @default.
• W4312185364 cites W3134102052 @default.
• W4312185364 cites W3196526948 @default.
• W4312185364 cites W4232375814 @default.
• W4312185364 cites W4234374651 @default.
• W4312185364 cites W4296231726 @default.
• W4312185364 doi "https://doi.org/10.2196/preprints.45244" @default.
• W4312185364 hasPublicationYear "2022" @default.
• W4312185364 type Work @default.
• W4312185364 citedByCount "0" @default.
• W4312185364 crossrefType "posted-content" @default.
• W4312185364 hasAuthorship W4312185364A5000866302 @default.
• W4312185364 hasAuthorship W4312185364A5012265247 @default.
• W4312185364 hasAuthorship W4312185364A5012781036 @default.
• W4312185364 hasAuthorship W4312185364A5013706735 @default.
• W4312185364 hasAuthorship W4312185364A5015162191 @default.
• W4312185364 hasAuthorship W4312185364A5020202420 @default.
• W4312185364 hasAuthorship W4312185364A5020934376 @default.
• W4312185364 hasAuthorship W4312185364A5056084508 @default.
• W4312185364 hasAuthorship W4312185364A5059578423 @default.
• W4312185364 hasAuthorship W4312185364A5064557855 @default.
• W4312185364 hasAuthorship W4312185364A5067401723 @default.
• W4312185364 hasAuthorship W4312185364A5070074773 @default.
• W4312185364 hasAuthorship W4312185364A5070680281 @default.
• W4312185364 hasAuthorship W4312185364A5081040113 @default.
• W4312185364 hasAuthorship W4312185364A5083087105 @default.
• W4312185364 hasAuthorship W4312185364A5085214715 @default.
• W4312185364 hasBestOaLocation W43121853642 @default.
• W4312185364 hasConcept C103038586 @default.
• W4312185364 hasConcept C117437137 @default.
• W4312185364 hasConcept C121608353 @default.
• W4312185364 hasConcept C126322002 @default.
• W4312185364 hasConcept C168563851 @default.
• W4312185364 hasConcept C171687745 @default.

• next